Using publicly available AML patient profiling arrays (Verhaak et al, 2009) and focussing on specific molecular abnormalities found in cytogenetically normal AML (CN-AML), we observed that MYB expression levels are highest in those patients carrying biallelic CEBPA mutations (Fig 1A). Here, MYB is linked to acute myeloid leukemia.